Literature DB >> 12402332

A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.

Catherine M Phelan1, Elaine Kwan, Elaine Jack, Song Li, Cindy Morgan, Jennifer Aubé, Danielle Hanna, Steven A Narod.   

Abstract

The 185delAG and 5382insC founder mutations account for the majority of mutations identified in BRCA1 in Ashkenazi Jewish breast and breast-ovarian cancer families. Few non-founder BRCA1 mutations have been identified to date in these families. We initially screened a panel of 245 Ashkenazi Jewish breast-ovarian cancer families with an affected proband and at least one other case of breast or ovarian cancer for founder mutations in BRCA1 and BRCA2. Founder mutations were identified in 85 families (185delAG in 44 families, 5382insC in 16 families, and the BRCA2 6174delT in 25 families). The 160 negative families were then screened for the entire BRCA1 gene by a combination of DGGE and PTT. We identified one novel frameshift mutation in BRCA1 in exon 14 (4572del22) that truncated the protein at codon 1485. The family contained three cases of early-onset ovarian cancer (41 years, 43 years, and 52 years) and one case of breast cancer (at age 54 years subsequent to an ovarian cancer). In addition, three missense variants of unknown significance (exon 11 C3832T (P1238L), exon 15 G4654T (S1512I), and exon 15 G4755A (D1546N)) were found in single families. These missense variants have been previously identified in other families [BIC Database] and are considered to be "unclassified variants, favoring polymorphism." Non-founder BRCA1 mutations are rare in Ashkenazi Jewish breast/ovarian cancer families. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12402332     DOI: 10.1002/humu.10123

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  22 in total

1.  Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals.

Authors:  Sarah M Nielsen; Lenika M De Simone; Olufunmilayo I Olopade
Journal:  J Genet Couns       Date:  2018-06-26       Impact factor: 2.537

2.  To reflex or not: additional BRCA1/2 testing in Ashkenazi Jewish individuals without founder mutations.

Authors:  Nancie Petrucelli; Sarah Mange; Jennifer L Fulbright; Lindsay Dohany; Dana Zakalik; Debra Duquette
Journal:  J Genet Couns       Date:  2014-09-09       Impact factor: 2.537

3.  No Evidence for the Pathogenicity of the BRCA2 c.6937 + 594T>G Deep Intronic Variant: A Case-Control Analysis.

Authors:  Julie Dutil; Lenin Godoy; Rafael Rivera-Lugo; Nelly Arroyo; Elinette Albino; Luis Negrón; Alvaro N Monteiro; Jaime L Matta; Miguel Echenique
Journal:  Genet Test Mol Biomarkers       Date:  2018-01-22

4.  Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer.

Authors:  Gabriela Torres-Mejía; Robert Royer; Marcia Llacuachaqui; Mohammad R Akbari; Anna R Giuliano; Louis Martínez-Matsushita; Angélica Angeles-Llerenas; Carolina Ortega-Olvera; Elad Ziv; Eduardo Lazcano-Ponce; Catherine M Phelan; Steven A Narod
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-04       Impact factor: 4.254

5.  Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.

Authors:  Luna Kadouri; Ayala Hubert; Yakir Rotenberg; Tamar Hamburger; Michal Sagi; Chovav Nechushtan; Dvorah Abeliovich; Tamar Peretz
Journal:  J Med Genet       Date:  2007-02-16       Impact factor: 6.318

6.  Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin.

Authors:  Luna Kadouri; Mark Temper; Tal Grenader; Dvorah Abeliovich; Tamar Hamburger; Tamar Peretz; Michal Lotem
Journal:  Fam Cancer       Date:  2008-08-05       Impact factor: 2.375

7.  BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.

Authors:  Rinske Drost; Kiranjit K Dhillon; Hanneke van der Gulden; Ingrid van der Heijden; Inger Brandsma; Cristina Cruz; Dafni Chondronasiou; Marta Castroviejo-Bermejo; Ute Boon; Eva Schut; Eline van der Burg; Ellen Wientjens; Mark Pieterse; Christiaan Klijn; Sjoerd Klarenbeek; Fabricio Loayza-Puch; Ran Elkon; Liesbeth van Deemter; Sven Rottenberg; Marieke van de Ven; Dick H W Dekkers; Jeroen A A Demmers; Dik C van Gent; Reuven Agami; Judith Balmaña; Violeta Serra; Toshiyasu Taniguchi; Peter Bouwman; Jos Jonkers
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

Review 8.  The contribution of BRCA1 and BRCA2 to ovarian cancer.

Authors:  Susan J Ramus; Simon A Gayther
Journal:  Mol Oncol       Date:  2009-02-10       Impact factor: 6.603

9.  The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.

Authors:  Maurizia Dalla Palma; Susan M Domchek; Jill Stopfer; Julie Erlichman; Jill D Siegfried; Jessica Tigges-Cardwell; Bernard A Mason; Timothy R Rebbeck; Katherine L Nathanson
Journal:  Cancer Res       Date:  2008-08-14       Impact factor: 12.701

10.  Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.

Authors:  Filipa Lynce; Claudine Isaacs
Journal:  J Natl Compr Canc Netw       Date:  2016-06       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.